CLINICAL SIGNIFICANCE OF THE VEGFR-2 IN THE TUMORS AND BLOOD SERA OF THE BREAST CANCER PATIENTS
https://doi.org/10.17650/1994-4098-2008-0-1-28-32
Abstract
The analysis of the changes of the content of the angiogenic factor VEGFR-2 in the cytosol of the tumor and blood sera of the 30 breast can- cer patients determined by immunoenzyme method during neoadjuvant therapy is given. Likewise the correlation of this index with the main clinicomorphological characteristics of the disease is assessed. The obtained results suggest on the possibility of the use of VEGFR-2 as the one of the diagnostic markers of the breast cancer. The index dynamics didn’t depend on the given therapy type but nonetheless the correlation of the VEGFR-2 content in the residual tumor after preoperative therapy with the grade of the treatment pathomorphosis is determined.
About the Authors
E. A. Kim
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
A. M. Platova
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
I. V. Visotzkaya
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
E. S. Gershteyn
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
V. P. Letyagin
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
N. E. Kushlinskiy
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
E. E. Mironova
Scientific and Research Institute of Clinical Oncology of N.N. Blokhin Cancer Research Center of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Герштейн Е.С., Кушлинский Н.Е. Биологические маркеры рака молочной железы: методологические аспекты и клинические рекомендации. Маммология 2005;(1):65—70.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27—31.
3. Кушлинский Н.Е., Герштейн Е.С. Роль фактора роста эндотелия сосудов при раке молочной железы. Бюлл эксп биол мед 2002;133(6):604—12.
4. Ferrara N. The role of VEGF in the regulation of physiological and pathologi- cal angiogenesis. EXS 2005;94:209—31.
5. Gasparini G. Prognostic value of vascu- lar endothelial growth factor in breast can- cer. Oncologist 2000;5 (Suppl. 1):37—44.
6. Linderholm B.K., Lindh B., Beckman L. et al. Prognostic correlation of basic fibrob- last growth factor and vascular endothelial growth factor in 1307 primary breast can- cers. Clin Breast Cancer 2003;4(5):340—7.
7. Relf M., LeJeune S., Scott P.A. et al. Expression of the angiogenic factors vas- cular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57(5):963—9.
8. Toi M., Inada K., Suzuki H. et al. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36(2):193—204.
9. Foekens J.A., Peters H.A. et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast can- cer. Cancer Res 2002;61(14):5407—14.
10. Жукова Л.Г., Жуков Н.В., Личиницер М.Р. Экспрессия рецепторов VEGF FLT-1 и FLK-1 на опухолевых клетках — новый фактор прогноза при местно-распространенном раке молочной железы. Бюлл эксп биол мед 2003;135(5):478—81.
11. Devries C., Escobedo J.A., Ueno H. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989—91.
12. Speirs V., Atkin S.L. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cul- tures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999;80(5—6):898—903.
13. Shibuya M., Ito N., Claesson-Welsh L. Structure and function of vascular endothe- lial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59—83.
14. Terman B.I., Vermazen M.D., Carrion M.E. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;34:1578—86.
15. Щербаков А.М., Герштейн Е.С., Анурова О.А., Кушлинский Н.Е. Фактор роста эндотелия сосудов и его рецепторы первого и второго типа при раке молочной железы. Вопр онкол 2005;51(3):317—21.
16. Ryden L., Jirstrom K., Bendahl P.O. et al. Tumor-specific expression of vascular endothelial growth factor receptor-2 but not vascular endothelial growth factor or human epidermal growth factor receptor-2 is asso- ciated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23(21):4695—704.
Review
For citations:
Kim E.A., Platova A.M., Visotzkaya I.V., Gershteyn E.S., Letyagin V.P., Kushlinskiy N.E., Mironova E.E. CLINICAL SIGNIFICANCE OF THE VEGFR-2 IN THE TUMORS AND BLOOD SERA OF THE BREAST CANCER PATIENTS. Tumors of female reproductive system. 2008;(1):28-32. (In Russ.) https://doi.org/10.17650/1994-4098-2008-0-1-28-32
Views:
450
Email this article 